Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
CGTN: China, ROK to strengthen exchanges on welfare for women and children
BEIJING, Jan. 7, 2026 /PRNewswire/ -- CGTN published an article focusing on…
Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys for the Treatment of ADHD
SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
CGTN: Extraordinary Navigation: How China strides forward with confidence
BEIJING, Jan. 3, 2026 /PRNewswire/ -- The Innovation-driven development is reshaping a…
Nexteer Sponsored Automotive Chassis-by-Wire Standards Research Group Meeting, Advancing Steer-by-Wire Standards in China
AUBURN HILLS, Mich. and SUZHOU, China, Dec. 31, 2025 /PRNewswire/ -- Nexteer…
Inside China | Kishore Mahbubani: APEC meeting in Shenzhen could inspire global development
GUANGZHOU, China, Dec. 30, 2025 /PRNewswire/ -- News report from South: Shenzhen…
“Nihao China” App Launches as an All-in-One Solution for International Visitors
HAIKOU, China, Dec. 24, 2025 /PRNewswire/ -- At the China International Travel Mart…
CGTN: How China drives high-quality development through technological innovation
BEIJING, Dec. 22, 2025 /PRNewswire/ -- CGTN published an article on how…
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
December 17, 2025 20:48 ET | Source: InnoCare Pharma BEIJING, Dec. 17,…
Xinhua Silk Road: Conference held in E. China biz hub to highlight burgeoning regional M&As
BEIJING, Dec. 15, 2025 /PRNewswire/ -- When gaining speed in building a…
